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http:WHAT THIS PAPER ADDS
The study presents a new method for delivering ultra-high-dose, short term thrombolysis with rt-PA for acute
lower limb ischemia.Objectives: The evaluation of success and complication rates of ultra high-dose recombinant tissue plasminogen
activator (rt-PA) administered over a short time frame in the treatment of acute lower limb ischemia.
Methods: This was a prospective single-center study. The outcome of treatment in 97 patients with acute limb
ischemia (<14 days) with the use of catheter directed rt-PA infusion was evaluated. The mean total dose of rt-PA
was 54.1 mg (50e60 mg) and was administered for a mean of 2.51 hours (2e4 hours). Thrombolytic success was
deﬁned as 95% thrombolysis of an occluded segment with return of antegrade ﬂow. Thirty-day complication and
amputation-free survival rates were calculated.
Results: Thrombolytic success was achieved in 83.5%. Overall clinical success was 88.7%.
The 30-day amputation-free survival rate was 93.8%. Major bleeding complications occurred in 10 patients
(10.3%). There were two deaths (2.1%) and four amputations (4.1%). Long-term amputation-free survival was
70%.
Conclusions: Administration of ultra-high doses of rt-PA over a short time period gives promising results. Such
delivery improves patient tolerance by rapid restoration of limb perfusion; however further studies are required
to conﬁrm these results.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Intra-arterial thrombolytic treatment is a commonly utilized
treatment modality in acute lower limb ischemia. It can
offer deﬁnitive treatment without the need for major sur-
gery in patients with acute ischemia due to occlusion of a
native artery or a bypass graft. Three randomized trials:
Rochester, STILE, and TOPAS, which compared intra-arterial
catheter-directed thrombolysis to standard surgical revas-
cularization in lower limb ischemia, have been published.1e
3 They have proved the beneﬁts of thrombolytic treatment
in acute ischemia compared with surgery. Particularly
beneﬁcial in thrombolysis is the detection of the cause of
arterial or bypass graft occlusion and the use of endovas-
cular techniques such as balloon angioplasty and/or stent-
ing to address the cause of the occlusion. Unfortunately,responding author. A. Falkowski, Pomeranian Academy of Medicine,
ment of Interventional Radiology, Al. Powstanców Wlkp 72, 70-111
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il address: bakhis@hot.pl (A. Falkowski).
-5884/$ e see front matter  2013 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2013.04.016despite good results, the administration of a thrombolytic
agent involves a small risk of serious complications.
The main complications are major bleeding and intra-
cranial hemorrhage.
There are many regimens of thrombolytic agent admin-
istration. Long-term infusion is the most often used. For
recombinant tissue-type plasminogen activator (rt-PA), the
most frequently utilized regimen is 1 mg/hour or 0.05 mg/
kg/hour.4 The use of these regimens often results in pro-
tracted treatment, which involves longer hospitalization,
increased risk of bleeding around the access point, and
thrombotic access vessel complications as well as the need
for more complicated treatment strategies in the event of
failure of thrombolysis. Of importance is the fact that during
thrombolytic treatment, temporary deterioration of
ischemia and the patient’s general condition may occur.
Protracted restoration of limb perfusion may mandate
surgery rather than thrombolysis, because thrombolytic
treatment, due to delayed revascularization, may result in
tissue ischemia and infarction before patency in the artery
is restored.3
For thrombolysis to be perceived as more valuable than
surgery, it would have to restore patency more rapidly and
A. Falkowski et al. 119increase patient comfort without increasing the rate of
adverse events. The aim of the current study was to assess
ultra-high-dose rt-PA administered over an ultra-short time
period in the treatment of acute lower limb ischemia.MATERIALS AND METHODS
Study group
Patients with acute limb ischemia lasting <14 days were
included in the study. The lesions concerned native vessels
and bypass grafts below the inguinal ligament. The patients
had to be aged over 18 years. Pregnant women or those
likely to be pregnant were excluded. An additional condition
was successful passage of a guidewire through the occluded
segment of the vessel. Patients with absolute and relative
contraindications to thrombolysis were excluded from the
study (Table 1). The investigators were physicians experi-
enced in thrombolytic techniques. The study was approved
by the Bio-ethical Committee of the Pomeranian Academy
of Medicine. The study was conducted according to the
guidelines for good clinical practice of research in the
Declaration of Helsinki.Study end points
The main aim was the evaluation of ultra-high-dose short-
term thrombolytic treatment in terms of limb salvage,
mortality, complications and requirements for additional
intervention. According to the indications of the Working
Party on Thrombolysis In the Management of Limb Ischemia
and the Society of Interventional Radiology Technology
Assessment Committee published in 2003,4 we assessed
separate end points. The primary end point of the study was
amputation-free survival. Secondary end points were the
degree of thrombolysis (in terms of reduction in thrombus
burden) and the rate of adverse effects of the treatment,
including hemorrhagic complications and additional surgical
interventions.Deﬁnitions
Technical success. Technical success was deﬁned on the
basis of angiography performed directly after the procedureTable 1. Exclusion criteria.
Active bleeding
Gastrointestinal bleeding, hematuria <10 days
Stroke and transient ischemic attack <2 months
Neurosurgery and intracranial trauma <3 months
Uncontrolled hypertension (>180/110 mmHg)
Brain tumor
Intracranial vascular malformation or aneurysm
Cardiopulmonary resuscitation or major surgery
or trauma <10 days
Recent eye surgery
Coagulopathy
Graft infection
Pregnancy
Uncooperative patientas restoration of antegrade ﬂow and reduction of thrombus
burden by more than 95% by volume.
Clinical success. Clinical success was deﬁned as technical
success and relief of acute ischemic symptoms at 30 days.
Overall clinical success. Overall clinical success was deﬁned
as relief of acute ischemic symptoms and the patient’s re-
turn to at least his/her pre-occlusive clinical baseline level
after thrombolysis and adjunctive procedures.
Complications. Major complications were deﬁned as events
leading to death, life-threatening conditions, conditions
resulting in potential disability, need for prolonged hospi-
talization, and/or requiring an additional procedure. Minor
complications were deﬁned as those which did not fulﬁll the
criteria for major complications. Major hemorrhagic com-
plications were deﬁned as intracranial hemorrhage, bleeding
resulting in death, those requiring surgery or transfusion, and
bleeding mandating cessation of thrombolytic therapy. Mi-
nor hemorrhagic complications were deﬁned as less serious
bleeding, managed by local compression or by increasing the
size of the vascular sheath. Non-hemorrhagic complications
included embolization requiring intervention, rethrombosis,
compartment syndrome, renal insufﬁciency, and acute
myocardial infarction.Technique
Complete arteriography of the lower limbs was performed
via a contralateral puncture. A 6F introducer and 5F cath-
eter were used. Using cross-bifurcation access, a guide was
passed through the thrombus, and a multiple side-hole
catheter (Infusion set, Cook Medical, Bloomington, IN,
USA; Infusion system, Angiodynamics, Latham, NY, USA)
with a guidewire tip obturator was placed directly into the
thrombus. The distal end of the catheter was placed in the
distal part of the thrombus. During the procedure, 2500 IU
of heparin (Polfa SA, Warsaw, Poland) was routinely
administered. An Actilyse (rt-PA, 0.2 mg/mL) dilution was
used for thrombolysis (Boehringer Ingelheim, Ingelheim,
Germany).
Fifteen milligrams of rt-PA was administered employing a
pulse-spray technique for 1 mg/minute for 15 minutes in
the treatment room and then 35 mg for 2 hours in constant
infusion with a syringe driver in the surgical ward. During
that time, the patient was given heparin 500 U/hour. After
this we evaluated the adequacy of lysis with further an-
giograms in the intervention suite. If residual thrombus was
angiographically evident, a further 10 mg was administered
for another 2 hours. Percutaneous transluminal angioplasty
(PTA) or stenting was performed after thrombolysis, if
necessary. Mechanical thrombectomy devices were not
used. All patients had the same indications concerning anti-
aggregate and anti-thrombotic therapy during and after the
procedure. During hospitalization, low molecular weight
heparin (Clexane, Sanoﬁ-Aventis, Paris, France) was used.
Then oral acetylsalicylic acid and clopidogrel in a dose of
75 mg/24 hours were recommended. Blood pressure, pulse,
Table 3. Baseline patient characteristics and comorbidities.
Characteristic Patients (%)
Male 71
Female 29
120 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 1 July/2013oxygen saturation, puncture site, and condition of the
ischemic limb were routinely monitored during the proce-
dure. Furthermore, hemoglobin, hematocrit, urea, and
creatinine were measured.Mean age (years) 67.3 (38e83)
Cardiac disease 46
Diabetes 28
Hypertension 56
Hyperlipidemia 32
Current smoker 56Statistical methods
For statistical analysis the chi square test or Fisher exact test
was used. A p value < .05 was considered statistically
signiﬁcant.Cerebrovascular disease 12
Table 4. Clinical characteristics of the patient.
Characteristic Patients (%)
The number of patients 97
Location of occlusion
Femoral 35.1
Femoropopliteal 44.3
Popliteal 9.3RESULTS
From May 2009 to May 2011, 343 patients with acute limb
ischemia were admitted to the Department of Vascular
Surgery at the Pomeranian Medical University. Of these, 97
qualiﬁed for thrombolytic treatment. Patients who had
conservative treatment, patients with severe ischemia
requiring immediate surgery, those with upper limb
ischemia, and with occlusion in the aorto-iliac segment, and
patients without run-off did not qualify. The number of
included and excluded patients is presented in Table 2. The
procedures were performed at the Interventional Radiology
Department of the Pomeranian Medical University.
Patients who qualiﬁed for the studies had symptoms of
acute limb ischemia, category I, IIa, and IIb according to the
Society of Vascular Surgery. Demographic and clinical data
of the patients are presented in Tables 3 and 4. There were
52 occluded vascular prostheses and 45 occluded arteries.
The most commonly treated zone was the femoropopliteal
segment in (43 patients). The majority of patients demon-
strated symptoms of acute ischemia classiﬁed as IIa (85
patients). Within a mean time of 2.51 hours, 54.1 mg of rt-
PA was administered on average. In 62 patients, angioplasty
and stent insertion were performed as an adjunct during
the lysis procedure. Four patients required surgical inter-
vention. Occlusion of an old femoral bypass at the site of
puncture occurred in one patient during the procedure.
Despite successful thrombolysis of the bypass, the patient
required surgical repair at the site of puncture. In two cases,
evacuation of hematoma at the puncture site, with an open
repair of the common femoral artery was necessary. One
case required fasciotomy. The mean time of hospitalizationTable 2. Patients with acute limb ischemia treated during the study
period.
The number of
patients
with acute limbs
ischemia
Total 343
Not qualiﬁed for the study 233
Qualiﬁed for the study 110
Excluded from thrombolysis 13
Contraindications (hematuria, TIA, 2
hypertension, trauma)
5
Failed guidewire passage 8
Thrombolytic treatment 97
TIA ¼ transient ischemic attack.was 6 days. Pretreatment and post-treatment ankle brachial
indexes were 0.0 (0.0e0.5) and 0.9 (0.0e1.2), respectively.
The overall technical success rate was 83% and the clinical
success rate was 82.5%. Among the patients in whom
technical success was not achieved (16 patients), four un-
derwent amputation. There was one death due to post-
operative complications. Six patients required surgical
revascularization (bypass graft or thrombectomy) and ﬁve
were left with persistent non-life-threatening ischemia.
During the ﬁrst 30 days, amputation-free survival was
93.8% (91 patients). The overall clinical success rate was
88.7%. Amputation-free survival rate at 1 year was 82.5%
and 70% at 2 years (Fig. 1).
Statistical analysis showed that the factors contributing
to poorer results were age, diabetes, and the severity of
limb ischemia (Table 5).Complications
The main complication was bleeding, which occurred in 10
patients (10.3%). A hematoma at the site of puncture was
the most frequent complication. There was onePopliteal-crural 11.3
Type of occlusion
Native artery 46.4
Bypass graft 53.6
Interventions
PTA/stenting 63.9
Surgery 4.1
SVS classiﬁcation
IIa 87.6
IIb 12.4
Mean rt-PA dose (mg) 54.1
Mean infusion time (hours) 2.51
Thrombotic occlusion 85
Embolism 15
rt-PA ¼ recombinant tissue-type plasminogen activator;
PTA ¼ percutaneous transluminal angioplasty, SVS ¼ Society of
Vascular Surgery.
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Figure 1. Amputation-free survival. KaplaneMeier percentages of patients surviving without amputation. The tick marks indicate censored
data. Numbers below time axis denote patients at risk at the respective time point.
A. Falkowski et al. 121gastrointestinal bleed and one epistaxis. Two patients
required surgical evacuation of a hematoma. In one patient,
a fatal intracranial hemorrhage occurred. Non-vascular
complications included one case of renal failure and one
case of compartment syndrome where fasciotomy was
necessary. A relatively high number of distal embolizations
6.2% (6 patients) was encountered. In these patients,
endovascular revascularization was successfully performed.DISCUSSION
There are a lot of studies detailing the beneﬁts of guided
thrombolytic treatment in acute limb ischemia. In someTable 5. Factors associated with clinical success.
Clinical success
Yes
(n ¼ 80)
No
(n ¼ 17)
Age < 70 (yes/no) 43/37 4/13 0.024
Sex (male/female) 55/25 14/3 0.379*
Location of occlusion (F/P) 65/15 12/5 0.334*
Occluded vessel (N/B) 39/41 6/11 0.312
Type of occlusion (T/E) 67/13 15/2 1.000*
SVS (IIa/IIb) 73/7 12/5 0.033*
Cardiac disease (yes/no) 35/45 10/7 0.258
Diabetes (yes/no) 18/62 9/8 0.017*
Hypertension (yes/no) 45/35 9/8 0.803
Current smoker (yes/no) 46/34 8/9 0.431
Cerebrovascular disease
(yes/no)
9/71 3/14 0.436*
GFR <60 (yes/no) 38/42 8/9 0.974
B ¼ bypass graft; E ¼ embolus; F ¼ femoral þ femoropopliteal;
N ¼ native; P ¼ popliteal þ popliteal-crural; T ¼ thrombus;
GFR ¼ glomerular ﬁltration rate.*Fisher exact 2-tailed p value.large trials which compared thrombolytic treatment with
surgical revascularization, a decrease in mortality in patients
randomized to lytic therapy was observed.2,3,5 Other ran-
domized trials of thrombolysis have focused on the method
of infusion, the kind of ﬁbrinolytic agent and the dose.6e9
However, despite numerous publications, there is no
consensus that one of the techniques is superior to the
others, and the optimum dose, dosing regimen, and tech-
nique of administration of new thrombolytic agents have
not been ultimately determined.4,10e12 A review of the
literature shows that two main strategies of rt-PA dosing
have been used: weight-based and non-weight based.13e16
In our study, we did not use a weight-based protocol, but
selected a uniform dose for a deﬁned time.
There is a fear of administering high-dose thrombolytic
agents because of the risk of bleeding and stroke.4,12
Moreover, there are reports concluding that using a high
dose does not improve the outcome.13,15 Some authors
have reported that using high doses and pulse-spray regi-
mens reduced the time of thrombolysis, but were associ-
ated with increased bleeding complications.12 However,
more recent studies comparing high-dose thrombolysis with
conventional low-dose infusion showed contradictory re-
sults.7,8 A correlation between an increased complication
rate and a higher dose of thrombolytic agent was not
conﬁrmed.15,17 Plate et al.11 compared the results of high-
dose rt-PA delivered via pulse-spray infusion with low-
dose infusion of rt-PA in 121 patients with acute limb
ischemia. Adverse events were similar to those in the
earlier studies and there was no difference between the
groups. There was also no difference between the groups
for mortality, amputations, or amputation-free survival
rates. The results of this study proved that low-dose therapy
122 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 1 July/2013does not reduce the number of adverse events after
thrombolytic therapy. This ﬁnding is also supported by other
reports.8,10,17 Furthermore, there is evidence suggesting
that low-dose thrombolysis was no better than surgical
treatment.18
There are studies showing that the risk of major com-
plications increases with the duration of thrombolytic
infusion from 4% at 8 hours to 34% at 40 hours.19,20 Swi-
schuk et al.21 showed that the increased duration of infu-
sion was connected with serious hemorrhagic events.
The risk of bleeding has been correlated with decreased
levels of ﬁbrinogen and increased ﬁbrin degradation prod-
ucts, as seen in prolonged continuous infusions. Short in-
fusions at a higher dose may have fewer adverse bleeding
complications as there is less ﬁbrinogen depletion and less
systemic circulation of plasmin. On this basis, we designed a
new scheme of drug administration: pulse-spray bolus fol-
lowed by high dose, short-term infusion. The success rate
did not differ from previous studies and was above 80%.
However, it is worth noting that the prevalence of adverse
events including major bleeding events was no higher than
in the results of previous studies.5,10,14,16,21e23 The results
of our study are surprising, taking into account the short-
term delivery and high doses. This may indicate that a
longer administration time may be of more importance
than a high dose. Furthermore, a shorter time of adminis-
tration is associated with a lower overall dose of heparin,
inﬂuencing the risk of complications.3
Our method of delivery offers potential beneﬁts. Shorter
treatment times were achieved and, in case of failure, more
timely surgery, with a shorter duration of limb ischemia. It
should be noted that prolonged thrombolysis is often
troublesome and stressful for elderly patients. It has pre-
viously been shown that additional stress, provoked by
prolonged thrombolysis and additional interventions, may
be responsible for a higher incidence of cardiac events.11 A
fatal event occurred in one patient over 75 years suggesting
thrombolysis should be avoided in elderly patients.10,24
We performed laboratory studies to aid early diagnosis of
developing complications, but with short infusions we felt it
was pointless monitoring hemostatic parameters, since they
had an insufﬁcient predictive value as far as hemorrhagic
complications were concerned.Limitations
The main limitation of our study was the use of only one
dosing regimen, one standard technique of administration,
and one standard dilution with no control group.
CONCLUSION
This study does not support the superiority of ultra-high-
dose rt-PA administered over short time frames in limb
salvage over other methods of thrombolytic agent admin-
istration. This novel method of delivery was not associated
with unacceptably high rates of complications, and there
was an obvious beneﬁt in faster restoration of limb perfu-
sion, greater patient comfort/tolerance and more efﬁcientutilization of resources. The results suggest complications
may be associated with protracted infusion, rather than the
dose of the thrombolytic agent. Further studies may resolve
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